Roth Capital initiated coverage on InfuSystem with a new price target
$INFU
Medical/Dental Instruments
Health Care
Roth Capital initiated coverage of InfuSystem with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2025 | $12.00 | Buy | Roth Capital |
| 9/26/2024 | $13.00 | Buy | B. Riley Securities |
Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0
Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the
Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
3 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)
Roth Capital initiated coverage of InfuSystem with a rating of Buy and set a new price target of $12.00
B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00
Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00
The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)
Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0
Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the
Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev